Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | NGS for MRD detection in leukemia

Krystof Seferna • 21 Mar 2022
EBMT 2022
Leukemia

Krystof Seferna, MD, Charles University, University Hospital Motol, Prague, Czech Republic, comments on the benefits of using next-generation sequencing (NGS) over quantitative PCR (qPCR) to detect low measurable residual disease (MRD) levels in leukemia. Dr Seferna explains that NGS presents several advantages over qPCR, but it is still very expensive and not yet available in all laboratories. In a recent study, it was shown that verifying low qPCR MRD positivity after stem cell transplantation (SCT) with NGS was an accurate method to predict relapse. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals